Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 14/20 | 0.58 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889027 | 0.89 | IGF1R (0.60) | IGF1RTAS2R8 | |
| SCHEMBL3008275 | 0.81 | IGF1R (0.68) | IGF1RTAS2R8 | |
| SCHEMBL4881731 | 0.80 | IGF1R (0.57) | IGF1RTAS2R8LMNAALDH1A1MEN1 | |
| SCHEMBL4881565 | 0.79 | IGF1R (0.61) | IGF1RTAS2R8 | |
| SCHEMBL13039129 | 0.79 | IGF1R (0.67) | IGF1RTAS2R8ALDH1A1 | |
| SCHEMBL4884448 | 0.78 | IGF1R (0.55) | IGF1RTAS2R8 | |
| SCHEMBL4880836 | 0.77 | IGF1R (0.62) | IGF1RTAS2R8MEN1KMT2ARAB9A | |
| SCHEMBL13039186 | 0.77 | IGF1R (0.68) | IGF1RTAS2R8 | |
| SCHEMBL2937078 | 0.77 | IGF1R (0.75) | IGF1RTAS2R8 | |
| SCHEMBL4888702 | 0.76 | IGF1R (0.58) | IGF1RTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-01-24 | — | — | US | disclosed |
| EP-1773809-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010643-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | PRKAR2B, PRKG2, PRKG1 | IGF1R 878/4885TAS2R8 2990/4885LMNA 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.